Cargando…
A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial
BACKGROUND: Anthracycline-based treatment remains the backbone of chemotherapy for nonresectable soft tissue sarcomas (STS). More than 30 % of patients with STS are aged 60 years or older, limiting the choice of treatment to single-agent approaches for this elderly population. Hematological toxicity...
Autores principales: | Karch, Annika, Koch, Armin, Grünwald, Viktor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936293/ https://www.ncbi.nlm.nih.gov/pubmed/27387325 http://dx.doi.org/10.1186/s13063-016-1434-x |
Ejemplares similares
-
Pazopanib in rare histologies of metastatic soft tissue sarcoma
por: Kataria, Babita, et al.
Publicado: (2021) -
A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma
por: Kim, Miso, et al.
Publicado: (2018) -
Pazopanib: Approval for Soft-Tissue Sarcoma
por: Nguyen, Diana T., et al.
Publicado: (2013) -
Pazopanib for the treatment of soft-tissue sarcoma
por: Heudel, Pierre, et al.
Publicado: (2012) -
Pazopanib in advanced soft tissue sarcomas
por: Lee, Alex T. J., et al.
Publicado: (2019)